⌘K
Loading ticker…
Pacific Biosciences of California, Inc. · Healthcare · Measuring & Control Equipment
As of 2026-06-26, Pacific Biosciences of California, Inc. (PACB) has a 3-month relative strength percentile of 74 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 56. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 9.0%, relative volume 3.16×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 74, Market Stance is mixed at 47, A/D rating B
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
PACB is in a stage 1 base, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 14.0% / -2.2%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
PACB is held by 4 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $12M notional. Top 3 carry $25M.
Top 4 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $12M |
| IWMiShares Russell 2000 ETF | 0.01% | $9M |
| VXFVanguard Extended Market ETF | 0.01% | $5M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $552K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PACB Jan avg: 1.74% median: 2.50% win: 50% σ: 32.00% n: 4 2022-04-12 → 2026-05-29 | PACB Feb avg: -16.17% median: -16.59% win: 0% σ: 8.20% n: 4 2022-04-12 → 2026-05-29 | PACB Mar avg: -11.18% median: -20.03% win: 25% σ: 26.46% n: 4 2022-04-12 → 2026-05-29 | PACB Apr avg: -14.54% median: -8.46% win: 20% σ: 27.94% n: 5 2022-04-12 → 2026-05-29 | PACB May avg: -1.08% median: -6.29% win: 40% σ: 13.10% n: 5 2022-04-12 → 2026-05-29 | PACB Jun avg: -2.21% median: -7.03% win: 50% σ: 24.97% n: 4 2022-04-12 → 2026-05-29 (current) | PACB Jul avg: 14.96% median: 5.31% win: 50% σ: 24.29% n: 4 2022-04-12 → 2026-05-29 | PACB Aug avg: -4.77% median: -9.84% win: 25% σ: 28.48% n: 4 2022-04-12 → 2026-05-29 | PACB Sep avg: -1.28% median: -1.61% win: 25% σ: 20.45% n: 4 2022-04-12 → 2026-05-29 | PACB Oct avg: 32.47% median: 36.52% win: 75% σ: 45.25% n: 4 2022-04-12 → 2026-05-29 | PACB Nov avg: 12.94% median: 13.26% win: 50% σ: 23.16% n: 4 2022-04-12 → 2026-05-29 | PACB Dec avg: -7.95% median: -11.79% win: 25% σ: 17.87% n: 4 2022-04-12 → 2026-05-29 |